List of GLP-1 receptor agonists: difference between revisions
Diff·revision 9 → 10·05:06, 19 Dec 2024
Difference between revision 9 and revision 10 of List of GLP-1 receptor agonists. 3 lines changed; the page grew by 260 bytes.
| Revision 9 — 14:14, 29 Nov 2024 RedirectRini (talk) reconcile the list against the category; two articles were missing 2,606 bytes ±0 | Revision 10 — 05:06, 19 Dec 2024 RetatrutideRuben (talk) de-orphan 2,866 bytes +260 | ||
|---|---|---|---|
| 1 | {{Infobox list | 1 | {{Infobox list |
| 2 | | name = List of GLP-1 receptor agonists | 2 | | name = List of GLP-1 receptor agonists |
| + | 3 | | subtitle = Reference material | |
| 3 | | Scope = Agonists at the GLP-1 receptor, alone or with others | 4 | | Scope = Agonists at the GLP-1 receptor, alone or with others |
| 4 | | Excluded = DPP-4 inhibitors, which raise endogenous hormone | 5 | | Excluded = DPP-4 inhibitors, which raise endogenous hormone |
| ⋮ | ⋮ | ||
| 32 | | Mazdutide | Glucagon, GLP-1 | Investigational | | 33 | | Mazdutide | Glucagon, GLP-1 | Investigational | |
| 33 | | [[Retatrutide]] | GIP, GLP-1, glucagon | Investigational | | 34 | | [[Retatrutide]] | GIP, GLP-1, glucagon | Investigational | |
| + | 35 | ||
| + | 36 | These are treated at [[Dual incretin agonist]] and [[Triple agonist]]. Their receptor ratios are fixed by chemistry and are not comparable between publications, since reported potencies are assay-dependent.{{r|drucker2018}} | |
| 34 | 37 | ||
| 35 | == References == | 38 | == References == |